New CEO tasked with keeping Chapel Hill medtech on track to commercialization


The public company is under new leadership as it works to advance its surgical system to clinical trials and keep its stock from being delisted.

Previous Stroke awareness: Everything you should know (video)
Next Flood gates open on metro Denver housing inventory in June